Herein, we demonstrated that the RHO GTPase inhibitor DLC1 prevented gastric inflammation in vivo and counteracted the oncogenic actions of CagA, a major virulence factor of H. pylori and a risk factor for GC [14]. This evidence concerns the gene DLC1 and gastric cancer.